Medicine and Dentistry
ABVD
9%
Adverse Event
10%
Anaplastic Large Cell Lymphoma
13%
Autologous Stem Cell Transplantation
6%
B-Cell Lymphoma
6%
Bladder Cancer
6%
Breast Cancer
6%
Brentuximab Vedotin
33%
Cancer Research
5%
CHOP
10%
Cutaneous T Cell Lymphoma
9%
Diffuse Large B-Cell Lymphoma
6%
Diseases
15%
Doxorubicin
5%
Follicular Lymphoma
12%
Hazard Ratio
6%
Hematologic Malignancy
5%
Hodgkin's Lymphoma
38%
Hypoxia
9%
Ibritumomab Tiuxetan
11%
Immune Checkpoint Inhibitor
5%
Immune Response
9%
Immunotherapy
16%
Iodine 131
6%
Lymphocyte
6%
Malignant Neoplasm
5%
Metaphase
5%
Monoclonal Antibody
7%
Muscle Invasive Bladder Cancer
8%
Neoplasm
46%
Non-Hodgkin Lymphoma
19%
Noninferiority Trial
6%
Oropharyngeal Cancer
6%
Overall Survival
18%
Peripheral T-Cell Lymphoma
12%
Positron Emission Tomography
7%
Positron Emission Tomography-Computed Tomography
5%
Programmed Cell Death
8%
Programmed Death 1 Ligand 1
5%
Programmed Death-Ligand 1
6%
Progression Free Survival
11%
Radiation Therapy
100%
Radioimmunotherapy
26%
Rituximab
12%
Solid Malignant Neoplasm
5%
Stem Cell Transplant
6%
Systemic Therapy
7%
Tumor Cell
10%
Tumor Microenvironment
7%
Yttrium 90
6%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
6%
Anaplastic Large Cell Lymphoma
16%
B Cell Lymphoma
11%
Brentuximab Vedotin
27%
Chemotherapy
26%
Combination Therapy
6%
Cutaneous T Cell Lymphoma
12%
Cyclophosphamide
7%
Diffuse Large B Cell Lymphoma
6%
Disease
12%
Follicular Lymphoma
9%
Hematologic Malignancy
7%
Hodgkin Disease
14%
Ibritumomab Tiuxetan
9%
Immunoglobulin
5%
Immunotherapy
12%
Iodine-131
8%
Malignant Neoplasm
20%
Monoclonal Antibody
15%
Mouse
5%
Neoplasm
35%
Nonhodgkin Lymphoma
11%
Obinutuzumab
9%
Overall Survival
14%
Peripheral T Cell Lymphoma
9%
Progression Free Survival
14%
Remission
12%
Rituximab
36%
Solid Malignant Neoplasm
6%
Toll Like Receptor 7
9%
Tumor Model
6%
Yttrium 90
10%
Immunology and Microbiology
Agonist
14%
B Cell
15%
Brentuximab Vedotin
18%
Caspase
6%
CD20
10%
Cell Death
13%
Cyclophosphamide
6%
Host Immune Response
5%
Immune Response
20%
Immune System
5%
Immunosuppression
6%
Immunosuppressive Drug
7%
Immunotherapy
31%
Intravenous Immunoglobulin
7%
Iodine-131
6%
Lymphocyte Count
6%
Lymphoma Cell
14%
Macrophage
8%
Monoclonal Antibody
20%
Monospecific Antibody
6%
Mouse
13%
Myeloid
7%
Natural Killer Cell
5%
Obinutuzumab
9%
Overall Survival
11%
Positron Emission Tomography
7%
Programmed Death 1 Ligand 1
5%
Programmed Death-Ligand 1
10%
Progression Free Survival
10%
Rituximab
16%
Stem Cell Transplant
6%
Syngenic
9%
T Cell
20%
TLR7
7%
Toll-Like Receptor
13%
Tumor Cell
11%